Atrial natriuretic factor: A new diagnostic marker for right ventricular infarction?  by Mizgala, Henry F.
554 
Editorial Comment 
JACC Vol. 15, No. 3 
March 1, 1990554-6 
Atria1 Natriuretic Factor: A New 
Diagnostic Marker for Right 
Ventricular Infarction?* 
HENRY F. MIZGALA, MD, FRCPC, FACC 
Vancouver, British Columbia, Canada 
The discovery by de Bold et al. (1) of the heart’s role as an 
endocrine organ will add new dimensions to the understand- 
ing of circulatory homeostasis and the pathophysiology of 
acute and chronic disorders of the circulatory system. Gran- 
ules in the atria contain an immunoreactive peptide hor- 
mone, atria1 natriuretic factor, possessing potent vasodila- 
tor, natriuretic and diuretic properties. In addition, atria1 
natriuretic factor inhibits the angiotensin II-mediated release 
of aldosterone (2) and relaxes vascular smooth muscle (3). 
There is also evidence that atria1 natriuretic factor has direct 
negative inotropic effects on the myocardium (4,5). These 
properties may have profound hemodynamic effects in some 
patients with acute myocardial infarction. 
Studies in humans (6) and in experimental animals (7) 
have shown that atria1 stretch is a potent stimulus for the 
release of atria1 natriuretic factor. Thus far, a relatively small 
number of studies and a few brief reports have been pub- 
lished on the behavior of this peptide in the clinical setting of 
acute myocardial infarction. Most of these reports have been 
observational; the exact mechanisms and temporal pattern 
of release of atria1 natriuretic factor remain unknown, and its 
precise role in the pathophysiology of acute myocardial 
infarction is still conjectural. 
The present study. In this issue of the Journal, Robalino 
et al. (8) report on a cohort of patients with acute inferior 
myocardial infarction whose serial plasma levels of atria1 
natriuretic factor were measured on days 1, 2, 3 and 7 
postinfarction. They observed that atria1 natriuretic factor 
levels were significantly higher in the subgroup of patients 
with associated right ventricular infarction diagnosed by 
electrocardiographic, echocardiographic, hemodynamic and 
coronary arteriographic criteria. 
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This carefully executed prospective study was based on 
the following hypothesis. Sudden increases in right atria1 
pressure are associated with an elevation of plasma atria1 
natriuretic factor. Because right ventricular infarction is 
usually associated with an increase in right atria1 pressure, 
plasma atria1 natriuretic factor should be disproportionately 
increased in patients with inferior infarction complicated by 
right ventricular infarction. Atria1 natriuretic factor’s natri- 
uretic, diuretic and vasorelaxant properties could therefore 
play a role in the clinical manifestations of right ventricular 
infarction, a clinical syndrome characterized by high right 
atria1 pressure, diminished cardiac output, vasodilatation 
and hypotension. Thus, early elevation of plasma atria1 
natriuretic factor in this clinical setting might be a measur- 
able marker for the early diagnosis of right ventricular 
infarction. 
The authors’ hypothesis (8) is very logical and, although 
it appears to be supported by the data presented, careful 
scrutiny of the results reveals some worrisome flaws. Of the 
121 patients admitted with the diagnosis of acute inferior 
myocardial infarction during the period of study, 21 met the 
inclusion criteria. Of these, eight had well documented 
evidence of right ventricular infarction. However, for un- 
known reasons, plasma atria1 natriuretic factor levels were 
obtained in only six of the eight subjects on days 1 and 2, and 
one patient (Case 8) had disproportionately lower values at 
the time of sampling on both days. If Patients 2 and 3, for 
whom atria1 natriuretic factor levels were not determined, 
also had been found to have lower than expected values as 
had Patient 8, I doubt that the difference in atria1 natriuretic 
factor levels in the two groups on day 1 would have reached 
statistical significance. Unfortunately, the timing of plasma 
atria1 natriuretic factor determination in relation to the onset 
of acute myocardial infarction and to hemodynamic mea- 
surements was unstated in this group of patients. This is a 
crucial point in light of the recent evidence (9) showing that 
when plasma atria1 natriuretic factor is measured at fixed 
short intervals during the 48 h after acute myocardial infarc- 
tion, levels are elevated above normal after a short time, but 
drop to lower or normal levels 3 to 6 h after the onset of 
infarction, steadily rising to elevated levels 12 to 24 h later. 
This time course of plasma atria1 natriuretic factor levels 
has been observed by other investigators (10,ll) and may 
explain the low initial levels in Patient 8 of Group I and 
Patients 1 and 2 of Group II in this report. The reason for the 
drop after an initial rise is uncertain. It has been suggested 
that it may be caused by depletion of atrial natriuretic factor 
as a result of its massive release, with depletion of atria1 
granules after ventricular impairment and sudden atria1 
stretch (9). Another explanation is that ischemic cardiac 
tissue may cause massive release of atrial natriuretic factor 
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(9). After adaptation of atrial natriuretic factor synthesis to 
an elevated requirement, the peptide’s concentration in- 
creases again. The authors (8) cite two references that report 
an early rise followed by a drop in atria1 natriuretic levels in 
acute myocardial infarction (their References 29 and 30). 
without comment that this time course of the peptide’s 
release could have seriously influenced their overall results 
and conclusions. 
That right ventricular infarction complicating inferior 
infurction causes increased plusma atria1 natriuretic factor 
levels because of disproportionately high right utrial pres- 
sure is a plausible explanation consistent with current evi- 
dence. However, this is not clearly demonstrated by the data 
in this study. To support this hypothesis, it would have been 
necessary to show that in the right ventricular infarction 
group (Group I), right atria1 pressure was significantly higher 
than in the group without right ventricular infarction (Group 
II). Unfortunately. hemodynamic data were available for 
only two patients in Group II, making statistical comparison 
between the two groups impossible. Furthermore, the lack 
of a demonstrated correlation between plasma atria1 natri- 
uretic factor levels on day 1 and the hemodynamic variables 
(right atria1 pressure, left ventricular filling pressure, mean 
arterial pressure, cardiac index and systemic vascular resis- 
tance) is not surprising. The timing of the hemodynamic 
study and plasma sampling in relation to the onset of 
infarction is unknown. The hemodynamic data represented 
“initial” values only, the day 1 atrial natriuretic factor levels 
were available for only six patients, of whom one had lower 
than expected values, and the correlations did not take into 
account the time course of plasma atrial natriuretic factor 
release during the first 24 h after infarction. The data 
provided in this report show that in a group of 8 patients with 
right ventricular infarction, plasma atrial natriuretic factor 
levels on days I, 2, 3 and 7 were higher than in I3 patients 
with inferior infarction not involving the right ventricle. 
Other possible mechanisms for this difference are not dis- 
cussed. 
Mechanisms of atrial natriuretic factor release in acute 
infarction. Indeed, in acute myocardial infarction, the 
mechanism of atrial natriuretic factor release is far from 
clear. Matsubara et al. (12) found a greater correlation of 
elevated atria1 natriuretic factor levels with pulmonary cap- 
illary wedge pressure than with elevated right atria1 pres- 
sure. Tomoda (13). in a study of 34 patients admitted within 
6 h of acute myocardial infarction, found a good correlation 
between plasma atrial natriuretic factor levels and increased 
atria1 and pulmonary pressures, systemic and pulmonary 
vascular resistances and reduced cardiac output. There was 
a more significant increase in atria1 natriuretic factor levels in 
association with elevated pulmonary artery capillary wedge 
pressure than with right atria1 pressure, even in patients with 
hemodynamically apparent right ventricular myocardial in- 
farction. In the study of Tan et al. (9), serial atrial natriuretic 
factor levels were measured at fixed times during 48 h in 38 
patients admitted to the hospital within 4.4 h of the onset of 
symptoms. Multiple regression analysis indicated that the 
site of infarction did not significantly influence atrial natri- 
uretic factor levels at the time of admission or the individual 
patient’s mean level during the first 48 h. a measure of the 
release of the peptide during this period. Atria1 natriuretic 
factor levels on admission, as well as the individual patient’s 
mean level during the 48 h after myocardial infarction, 
appeared to correlate weakly but significantly with maximal 
creatine kinase values and with left ventricular function 
measured by gated blood pool scintigraphy (9). 
Role of complications in the study patients in the high 
plasma levels. I am also concerned by the high incidence of 
complications reported in the group with right ventricular 
infarction in this study (8). Of eight patients, six had hypo- 
tension unresponsive to intravenous fluid replacement and 
presumably required vasopressor therapy, five had evidence 
of atrioventricular (AV) dissociation, two had “clinical left 
heart failure” and one patient had biventricular failure and 
cardiogenic shock and died. In contrast, in the group without 
right ventricular infarction, only two patients had hypoten- 
sion requiring vasopressor therapy. two had “left heart 
failure” and one had AV dissociation. This is a major 
difference. How representative was this group of patients 
with inferior infarction complicated by right ventricular 
infarction’? More importantly, how did these complications 
influence the release and plasma levels of atrial natriuretic 
factor? We can only speculate. In our laboratory, Wong et 
al. (14) found that sinus node function and heart rate 
appeared to play an important role in atria1 natriuretic factor 
release. They also found that, in dogs, pacing at different 
heart rates influenced atria1 natriuretic factor release at 
constant atrial pressure (Wong et al., personal communica- 
tion). They (15) have also demonstrated that in isolated atrial 
preparations, alpha- and beta-adrenergic stimulation were 
potent stimuli of atria1 natriuretic factor release. In the 
present study, six of the eight patients with right ventricular 
myocardial infarction presumably required vasopressor ther- 
apy, an event that cannot be overlooked in analyzing these 
results. 
Conclusions. Study of the release of atria1 natriuretic 
factor and its role in the pathophysiology of acute myocar- 
dial infarction is a relatively new field of research. Consid- 
erable data have accumulated since the authors (8) began 
their study in February 1987, which in part explains some of 
the shortcomings of the protocol. Their initial hypothesis 
was valid. but in my view and for the reasons outlined, it is 
not supported by the data presented. The authors (8) have 
demonstrated high levels of atria1 natriuretic factor in a small 
cohort of patients with inferior infarction complicated by 
right ventricular infarction and in whom there was an exces- 
sive incidence of serious complications. These complica- 
tions and their management could have contributed at least 
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in part to the high atria1 natriuretic factor levels, independent 
of the site of infarction. In the absence of more precise data 
obtained in a larger sample of patients and with due consid- 
eration for the time course of atrial natriuretic factor release 
during the first day of acute myocardial infarction, it would 
be premature to consider a high plasma atria1 natriuretic 
factor level as an early marker for right ventricular involve- 
ment in patients with acute inferior myocardial infarction. 
Further studies are indeed required. 
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